2012-11-13 05:25:02 - Octapharma AG - SWOT, Strategy and Corporate Finance Report - a new company profile report on companiesandmarkets.com

Octapharma AG - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company´s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

- Detailed information on Octapharma AG required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Octapharma AG in the form of a SWOT analysis
- An in-depth view of the business model of Octapharma AG including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Octapharma AG
- Intelligence on Octapharma AGnv´s mergers

 

 

and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Octapharma AG, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Octapharma is an independent global plasma fractionation specialist. The group is engaged in the R&D of human proteins for various therapeutic areas, and provides products for the treatment of coagulation disorders and immune diseases, and offers intensive care and emergency medicines. The group operates in Europe, North and South Americas, Asia-Pacific and the Middle East. It is headquartered in Lachen, Switzerland and employed 4,238 people as of December 31, 2010. The company recorded revenues of E717.8 million ($952.3 million*) during the financial year (FY) ended December 2010, a decrease of 28.8% over FY2009. The operating profit of the company was E24.1 million ($32 million*) during FY2010, a decrease of 91.3% over FY2009. The net profit was E45.8 million ($60.8 million*) in FY2010, a decrease of 81.9% over FY2009. *Calculated using the constant conversion rate of E1 = $1.3267 for the financial year ended December 31, 2010.
Reasons to Purchase:

- Gain understanding of Octapharma AG and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Octapharma AG as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers´ businesses better
- Stay up to date on Octapharma AG´s business structure, strategy and prospects

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Company Profile Reports www.companiesandmarkets.com/Market/All/Company-Profile?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.